Oral Administration of Peptides; Absorption From Gastrointestinal Tract
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Context: Oral formulations of GLP-1 and PYY3-36, two satiety peptides, were studied. An oral
delivery system would be preferable in many of the possible therapeutic indications of these
peptides.
Objectives: Our objective was to establish the pharmacological profile of increasing oral
doses of GLP-1 and PYY3-36 in healthy volunteers. In addition, the pharmacological effects of
GLP-1 were investigated.
Setting: Single center escalating dose study with oral applications. Subjects and Methods: In
the first part, GLP-1 was given orally to 6 male subjects; the treatment consisted of one of
the following oral doses of either GLP-1 (0.5, 1.0, 2.0 and 4.0 mg) or placebo. In the second
part, PYY3-36 was given orally to another 6 healthy male subjects; the treatment consisted of
one of the following oral doses of either PYY3-36 (0.25, 0.5, 1.0, 2.0 and 4.0 mg) or
placebo.